Xtx Topco LTD Adaptimmune Therapeutics PLC Transaction History

Xtx Topco LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$0.83 - $1.47 $2,948 - $5,222	-3,553 Reduced 22.27%	12,399 $12,000
Q1 2024 May 13, 2024	SELL	$0.7 - $1.75 $14,717 - $36,793	-21,025 Reduced 56.86%	15,952 $25,000
Q4 2023 Feb 13, 2024	BUY	$0.43 - $0.79 $15,900 - $29,211	36,977 New	36,977 $29,000
Q1 2022 May 13, 2022	SELL	$1.73 - $4.06 $30,378 - $71,293	-17,560 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$3.5 - $5.68 $61,460 - $99,740	17,560 New	17,560 $66,000

145M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $96.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.